Conference Presentations
SORT BY PROGRAM
All   •   Cefepime-Taniborbactam   •   Ceftibuten-Ledaborbactam Etzadroxil   •   VNRX-9945

Gordon Research Conference

June 23 - 28, 2024
A new class of penicillin-binding protein inhibitors to address drug-resistant Neisseria gonorrhoeae

ASM Microbe 2024

June 13 - 17, 2024
In vitro activity of ceftibuten-ledaborbactam and comparators against Enterobacterales from a Phase 3 study of adults with complicated urinary tract infection (cUTI)
VNRX-14079, a cyclic boronate penicillin-binding-protein inhibitor, retains antibacterial and bactericidal activity against ceftriaxone-resistant Neisseria gonorrhoeae

ECCMID 2024

April 27 - 30, 2024
Outcomes at Test of Cure by baseline pathogen and cefepime-taniborbactam or meropenem MIC in the Phase 3 CERTAIN-1 study of patients with complicated urinary tract infection (cUTI)
Antimicrobial Activity of Cefepime in Combination with Taniborbactam against resistant clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in Europe, 2018-2022
In vitro activity of cefepime-taniborbactam and comparators against European isolates of Enterobacterales and P. aeruginosa with defined b-lactamase carriage, 2018-2022

Gordon Research Conference

March 17 - 22, 2024
A new class of penicillin-binding protein inhibitors to address PBP2-mediated resistance in Neisseria gonorrhoeae

IDWeek 2023

October 11 - 15, 2023
In Vitro Activity of Cefepime-Taniborbactamand Comparator Agents Against Gram-Negative Bacteria Isolated from Patients with Cancer
CERTAIN-1 Subgroup Analysis: A Phase 3 Study of Cefepime-Taniborbactam Efficacy and Safety in the Treatment of Complicated Urinary Tract Infections (cUTI)
Outcomes by Resistance Phenotype and Genotype among Baseline Pathogen in Patients with Complicated Urinary Tract Infection (cUTI) in the Phase 3 CERTAIN-1 Study
In vitro activity of aztreonam-avibactam, cefiderocol, and cefepime-taniborbactamagainst multi-species, NDM-producing Enterobacterales causing a local outbreak
Antimicrobial Activity of Cefepime in Combination 2122 Palmer Drive with Taniborbactam Against Resistant Clinical Isolates from the United States 2018-2021
In Vitro Activity of Cefepime-Taniborbactam and Comparators Against Genotypically Characterized Carbapenem-Resistant Enterobacterales (CRE) and Carbapenem-Resistant Pseudomonas aeruginosa (CRPA) from the United States, 2018-2021
Ceftibuten-Ledaborbactam Etzadroxil: Addressing the Need for an Oral Antibiotic to Treat Drug Resistant Enterobacterales

ASM/ESCMID 2023

September 19 - 22, 2023
Susceptibility Profiles of Baseline Gram-negative Pathogens from CERTAIN-1, a Phase 3 Study comparing Cefepime-taniborbactam to Meropenem in Adultswith Complicated Urinary Tract Infection (cUTI)

ASM Microbe 2023

July 20, 2023
Validation of Cefepime-Taniborbactam MIC Antimicrobial Susceptibility Test for MicroScan Dried Gram-Negative MIC Panels from a Multicenter Assessment of Enterobacterales and Pseudomonas aeruginosa

MAD-ID 2023

May 10 - 13, 2023
Cefepime-Taniborbactam Human Exposures Suppress the Emergence of Resistance among Cefepime-Nonsusceptible Enterobacterales and Pseudomonas aeruginosa in a Hollow Fiber Infection Model

ECCMID 2023

April 15 - 18, 2023
Activity of Cefepime-Taniborbactam (FTB) Against Enterobacterales and P. aeruginosa Collected Globally in 2018-2021 Stratified by β-lactamase Carriage
Antimicrobial Activity of Cefepime in Combination with Taniborbactam Against Resistant Clinical Isolates of Enterobacterales from 2018-2021 Global Surveillance

IDWeek 2022

October 19 - 23, 2022
In Vitro Activity of Cefepime-Taniborbactam and Comparators against a Global Collection of Carbapenem-Resistant Enterobacterales (CRE) and Carbapenem-Resistant Pseudomonas aeruginosa (CRPA) with and without Carbapenemases
Activities of Cefepime-Taniborbactam and Ceftazidime-Avibactam against Cefepime-Resistant Respiratory Gram-Negative Pathogens in a Hollow Fiber Infection Model
Development of Cefepime-Taniborbactam MIC Antimicrobial Susceptibility Test for Gram-Negative Bacteria on MicroScan Dried Gram-Negative MIC Panels
Antimicrobial Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates from ICU and Non-ICU Patients; 2018-2020 Global Surveillance
Cefepime -Taniborbactam: Addressing Current and Future Antimicrobial Resistance
A phase 3 Study of Cefepime-Taniborbactam Efficacy and Safety in the Treatment of Complicated Urinary Tract Infections (cUTI), including Acute Pyelonephritis (AP)

ASM Microbe 2022

October 12, 2022
In Vivo Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of Cefepime-Taniborbactam Combination against Cefepime-Resistant Enterobacterales and Pseudomonas aeruginosa in a Murine Pneumonia Model
Structural insights into potent inhibition of PDC-3 and PDC-88 β-lactamases by the bicyclic boronic acid inhibitor taniborbactam

ESCMID/ASM 2022

October 4 - 7, 2022
Cefepime-taniborbactam and comparator activity in vitro against carbapenem-resistant Enterobacterales (CRE), carbapenem-resistant Pseudomonas aeruginosa (CRPA) and multidrug-resistant (MDR) Enterobacterales and P. aeruginosa from 2018-2020 surveillance
Time to Change the Complicated Urinary Tract Infection Primary Endpoint? The problem and a potential solution

ECCMID 2022

April 23 - 26, 2022
P0631 -In vitro activity of ceftibuten in combination with VNRX-5236 against clinical isolates of Enterobacterales collected in 2018-2020
P0632 - In vitro activity of cefepime-taniborbactam against molecularly characterised Enterobacterales and P. aeruginosa collected worldwide from 2018-2020
P0633 - Antimicrobial activity of cefepime in combination with taniborbactam against resistant clinical isolates of Enterobacterales from 2018-2020 global surveillance

IDWeek 2021

September 29 - October 3, 2021
Oral Presentation 133 – ARGONAUT-III: Susceptibility of Carbapenem-resistant Klebsiellae to Cefepime-Taniborbactam
Oral Presentation 203 – Activity of Cefepime in Combination with Taniborbactam (formerly VNRX-5133) against Pseudomonas aeruginosa from a Global 2018-2020 Surveillance Collection
Poster Presentation 642 – Facility reported vs. CLSI MIC breakpoint comparison of Carbapenem non-susceptible (Carb-NS) Enterobacteriaceae (ENT) from 2016-2019: A multicenter evaluation
Poster Presentation 786 – Facility reported vs. CLSI MIC breakpoint comparison of Carbapenem non-susceptible (Carb-NS) Pseudomonas aeruginosa (PSA) from 2016-2019: A multicenter evaluation
Poster Presentation 1055 – ARGONAUT-IV: Susceptibility of Carbapenem-resistant Klebsiellae to Ceftibuten/VNRX-5236
Poster Presentation 1063 – ARGONAUT-V: Susceptibility of Multidrug-Resistant (MDR) Pseudomonas aeruginosa to Cefepime-Taniborbactam
Poster Presentation 1253 – Antimicrobial Activity of Cefepime in Combination with Taniborbactam (formerly VNRX-5133) Against Clinical Isolates of Enterobacterales from 2018-2020 Global Surveillance
Poster Presentation #1286 – Taniborbactam Inhibits Cefepime-Hydrolyzing Variants of Pseudomonas-derived Cephalosporinase (PDC)
Poster Presentation 1293 – In vitro Activity of Ceftibuten in Combination with VNRX-5236 against Clinical Isolates of Enterobacterales from Urinary Tract Infections Collected in 2018-2020

ECCMID 2021

July 9 - 12, 2021
Abstract 02128 – Cefepime-taniborbactam (formerly cefepime/VNRX-5133) demonstrates potent activity vs. Enterobacterales with blaOXA-48
Abstract 02144 – Examining the antimicrobial activity of cefepime-taniborbactam (formerly cefepime/VNRX-5133) against Burkholderia species isolated from cystic fibrosis patients in the United States
Abstract 02564 – Antimicrobial Activity of Cefepime in Combination with Taniborbactam (formerly VNRX-5133) Against a European 2018-2020 Surveillance Collection of Pseudomonas aeruginosa
Abstract 02581 – Antimicrobial Activity of Cefepime in Combination with Taniborbactam (formerly VNRX-5133) Against Clinical Isolates of Enterobacterales from Europe Collected from 2018-2020 Surveillance
Abstract 03198 – Evaluation of the in vitro activity of cefepime-taniborbactam against carbapenemase-producing Enterobacterales recovered in Spain
Abstract 03200 – Exploring the in vitro activity of cefepime/taniborbactam combination against metallo beta-lactamase producing Klebsiella pneumoniae and Pseudomonas aeruginosa isolates
Abstract 03285 – Assessment of activity of a novel orally bioavailable β-lactam/β-lactamase inhibitor combination, ceftibuten/VNRX-7145 (VNRX-5236 etzadroxil) against Enterobacterales carrying blaOXA-48
Abstract 03578 – Activity of cefepime-taniborbactam (formerly cefepime/VNRX-5133) and comparators against NDM-producing Enterobacterales from a regional outbreak

International Liver Congress 2021

June 23 - 26, 2021
Discovery and preclinical profile of VNRX-9945, a potent, broadly active core protein inhibitor for the treatment of chronic hepatitis B virus (HBV) infection

World Microbe Forum 2021

June 20 - 24, 2021
Association of Cefepime-Taniborbactam MICs and β-lactam Resistance Mechanisms Identified Using Whole Genome Sequencing of Ertapenem-nonsusceptible Enterobacterales Clinical Isolates: CANWARD 2007-2018
In Vitro Activity of Cefepime-Taniborbactam against Ertapenem-nonsusceptible Enterobacterales Obtained Across Canada: CANWARD 2007-2019
In Vivo Efficacy of Cefepime-Taniborbactam Against Beta-Lactamase-Producing Enterobacterales and Pseudomonas Aeruginosa in a Neutropenic Murine Complicated Urinary Tract Infection Model

IDWeek 2020

October 21 - 25, 2020
Poster 1318 - Pharmacokinetics and Safety of Cefepime-Taniborbactam (formerly Cefepime/VNRX-5133) in Subjects with Renal Impairment

ECCMID 2020

April 18 - 21, 2020
P0284 – A multi-site study comparing a commercially-prepared dried MIC susceptibility system to the CLSI/ISO broth microdilution method for cefepime-taniborbactam (formerly cefepime/VNRX-5133) using Gram-negative non-fastidious organisms
P2119 – Impact of porin deletions on the in vitro antimicrobial activity of cefepime-taniborbactam (formerly cefepime/VNRX-5133) in Klebsiella pneumoniae
P2737 - Antimicrobial Activity of Cefepime in Combination with Taniborbactam(formerly VNRX-5133) against a European 2018-2019 Surveillance Collection of Pseudomonas aeruginosa
P2738 – Antimicrobial Activity of Cefepime in Combination with Taniborbactam (formerly VNRX-5133) Against Clinical Isolates of Enterobacterales from Europe Collected from 2018-2019 Surveillance

ASM Microbe 2019

June 23, 2019
SUNDAY - AAR-719 - Rescue of Ceftibuten Activity by the Oral Beta-Lactamase Inhibitor VNRX-7145 against Enterobacteriaceae Expressing Class A, C and/or D Beta-Lactamases
SUNDAY - AAR-720 - The Orally Bioavailable Beta-Lactamase Inhibitor VNRX-7145 Restores Bactericidal Activity of Ceftibuten against Enterobacteriaceae Expressing Ambler Class A, C, and/or D Enzymes.
SUNDAY - AAR-721 - In Vitro Activity of Ceftibuten in Combination with VNRX-7145 and Comparators against 1,066 UTI Isolates Non-Susceptible to Amoxicillin-Clavulanate and Levofloxacin.
SUNDAY - AAR-722 - Antimicrobial Activity of Cefepime in Combination with VNRX-5133 against a Global 2018 Surveillance Collection of Pseudomonas aeruginosa.
SUNDAY - AAR-723 - Synergy/Antagonism of Ceftibuten/VNRX-7145 in Combination with Other Commonly Used Antimicrobial Agents in Gram-Negative Aerobic Bacteria, Anaerobic Bacteria, and Yeast.
SUNDAY - AAR-724 - In Vitro Permeability and Metabolic Biotransformation of Oral Beta-Lactamase Inhibitor VNRX-7145 across Species.
SUNDAY - AAR-726 - Efficacy of Ceftibuten + VNRX-7145, a Novel Beta-Lactamase Inhibitor against ESBL E. coli Strains in a Murine UTI Model
SUNDAY - AAR-727 - Assessment of the In Vivo Pharmacodynamic Profile of Ceftibuten (CTB)/VNRX-7145 Combination against Serine β-Lactamase-Producing Enterobacteriaceae (SBL-EB) in the Neutropenic Murine Thigh Infection Model
SUNDAY - AAR-728 - Oral Bioavailability of Novel Beta-Lactamase Inhibitor VNRX-7145 in Rats, Dogs and Non-Human Primates
SUNDAY - CPHM-860 - Impact of Variations in Susceptibility Testing Parameters on the In Vitro Activity of Ceftibuten in Combination with VNRX-7145 ECCMID 2019

ECCMID 2019

April 13 - 16, 2019
#O1061— Pharmacodynamics of VNRX-5133 in combination with cefepime studied in an in vitro model of infection.
#O1064 — In vivo pharmacodynamic profile of cefepime in combination with VNRX-5133 against serine beta-lactamase-producing Gram-negative bacteria in the neutropenic murine thigh infection model.
#P1175 — Antimicrobial activity of cefepime in combination with VNRX-5133 against a global 2018 surveillance collection of clinical isolates.
#P1176 — Antimicrobial activity of cefepime in combination with VNRX-5133 against a collection of beta-lactamase-producing Enterobacteriaceae.
#P1177 — Activity of cefepime/VNRX-5133 and comparators against an Italian nationwide collection of Pseudomonas aeruginosa from respiratory and bloodstream infections.
#P1178 — VNRX-5133 maintains potent inhibitory activity in engineered NDM-1 variants with increased cefepime hydrolytic efficiency.
#P1179 — Evaluation of the in vitro activity of cefepime plus VNRX-5133 and comparative agents against carbapenem-resistant Enterobacteriaceae.
#P1180 — In vitro activity of the orally available ceftibuten/VNRX-7145 combination against a challenge set of Enterobacteriaceae pathogens carrying molecularly characterised beta-lactamase genes.
#P1181 — Selection of ceftibuten as the partner antibiotic for the oral beta-lactamase inhibitor VNRX-7145.
#P1182 — Ceftibuten/VNRX-7145, an orally bioavailable beta-lactam/beta-lactamase inhibitor combination active against serine-beta-lactamase producing Enterobacteriaceae.
#P1183 — Oral ceftibuten/VNRX-7145 shows equivalent activity in vitro to IV therapeutics against MDR Enterobacteriaceae.
#P1951 — Pharmacokinetics of VNRX-5133 in Combination with Cefepime and Metronidazole.

IDWeek 2018

October 3 - 7, 2018
Poster 1360 – Antimicrobial Activity of Cefepime in Combination with VNRX-5133 Against a Global Collection of Enterobacteriaceae Including Resistant Phenotypes.
Poster 1370 – Cefepime/VNRX-5133 Broad-Spectrum Activity is Maintained against Emerging KPC- and PDC-Variants in Multidrug Resistant K. pneumoniae and P. aeruginosa.
Poster 1395 – Defining the Magnitude of AUC:MIC Driver for Efficacy of the beta-lactamase Inhibitor VNRX-5133 when combined with Cefepime against KPC- and VIM/NDM-producing Enterobacteriaceae and P. aeruginosa.
Poster 1401 – A Randomized, Double-blind, Placebo-controlled Study of the Safety and Pharmacokinetics of Single and Repeat Doses of VNRX-5133 in Healthy Subjects.
Poster 1405 – Efficacy of the Human-Simulated Regimen (HSR) of Cefepime (FEP)/VNRX-5133 Combination against Serine beta-lactamase-Producing Gram-negative Bacteria in the Neutropenic Murine Thigh Infection Model.

ASM Microbe 2018

June 7 - 11, 2018
FRIDAY 226 — Development of CLSI MIC and disk diffusion quality control ranges for Cefepime/VNRX-5133.
FRIDAY 609 — In vitro activity of cefepime in combination with VNRX-5133 against gram-negative UTI isolates.
FRIDAY 610 — Cefepime/VNRX-5133 retains potent activity against KPC variants responsible for recent clinical treatment failures of Ceftazidime/Avibactam in Klebsiella Pneumoniae.
FRIDAY 611 — Evaluation of the Impact of Variation in Standard Testing Parameters on the Activity of Cefepime in Combination with VNRX-5133.
FRIDAY 612 — Efficacy of cefepime combined with VNRX-5133, a novel broad-spectrum beta-lactamase inhibitor, against a cephalosporin-resistant ESBL E. coli in a murine UTI model

ECCMID 2018

April 21 - 24, 2018
#O0575 — Pharmacodynamics of the novel broad-spectrum beta-lactamase inhibitor VNRX-5133 in combination with cefepime in neutropenic female CD-1 mice with experimental pneumonia.
#O0600 — Efficacy of cefepime / VNRX-5133, a novel beta-lactamase inhibitor combination, against cephalosporin-resistant, ESBL-producing K. pneumoniae in a murine lung-infection model.
#O0603 — Structural basis for serine- and metallo-beta-lactamase inhibition by VNRX-5133, a new beta-lactamase inhibitor (BLI) in clinical development.
#O0606 — Kinetic mechanism and parameters of inhibition of serine KPC-2, CTX-M15, p99 AmpC and metallo VIM-2 by the broad-spectrum beta-lactamase inhibitor VNRX-5133.
#P1536 — Potentiation of cefepime by the boronate VNRX-5133 versus gram-negative bacteria with known beta-lactamases.
#P1537 — Pharmacokinetics-pharmacodynamics (PK-PD) of VNRX-5133, a broad-spectrum novel beta-lactamase inhibitor (BS-BLI), in combination with cefepime in a one-compartment in vitro infection model.
#P1538 — Efficacy of cefepime / VNRX-5133, a novel broad-spectrum beta-lactamase inhibitor, in a murine bacteremia infection model with carbapenem-resistant Enterobacteriaceae (CREs).
#P1539 — In vitro activity of cefepime alone and in combination with the broad-spectrum beta-lactamase inhibitor VNRX-5133 against ESBL and carbapenamases harbouring Enterobacteriaceae and Pseudomonas spp.
#P1540 | VNRX-5133, a novel broad-spectrum beta-lactamase inhibitor, enhances the activity of cefepime against Enterobacteriaceae and P. aeruginosa isolates in a neutropenic mousethigh infection model.
#P1541 | Susceptibility to cefepime / VNRX-5133 in 298 carbapenem-resistant Enterobacteriaceae producing serine- and metallo-beta-lactamases.
#P1542 | In vitro activity of cefepime in combination with VNRX-5133 against meropenem and/or cefepime resistant clinical isolates of Pseudomonas aeruginosa.
#P1543 | Antimicrobial activity of cefepime in combination with VNRX-5133 against a global collection of clinical isolates.
#P1544 | In vitro activity of cefepime in combination with VNRX-5133 when tested against cephalosporin and carbapenem resistant beta-lactamase producing gram-negative isolates.
#P1545 | The ability of broad-spectrum beta-lactamase inhibitor VNRX-5133 to restore bactericidal activity of cefepime in Enterobacteriaceae- and P. aeruginosa-expressing Ambler class A, B, C and D enzymes is demonstrated using time-kill kinetics.
You are using a browser that is not supported. Please consider changing your browser